Biomarker Studies

Urine proteomic insights from the belimumab in lupus nephritis trial

Emma Weeding, Andrea Fava, Chandra Mohan, Laurence Magder, Daniel Goldman, Michelle Petri

10.1136/lupus-2022-000763

September 27, 2022

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)

John Conklin, Michael Golpanian, Alexis Engel, Peter Izmirly, H Michael Belmont, Thierry Dervieux, Jill P Buyon, Roberta Vezza Alexander

10.1136/lupus-2022-000754

September 5, 2022

Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response

Jan-Mou Lee, Ming-Huang Chen, Kai-Yuan Chou, Yee Chao, Ming-Han Chen, Chang-Youh Tsai

10.1136/lupus-2022-000693

June 23, 2022

Phenotypical changes and clinical significance of CD4/CD8 T cells in SLE

Shiwen Yuan, Yanting Zeng, Jiawei Li, Cuicui Wang, Weinian Li, Zhixiang He, Jinghua Ye, Fangfei Li, Yi Chen, Xiaojun Lin, Na Yu, Xiaoyan Cai

10.1136/lupus-2022-000660

June 22, 2022

Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial

Stephen McDonald, Sean Yiu, Li Su, Caroline Gordon, Matt Truman, Laura Lisk, Neil Solomons, Ian N Bruce, for the MASTERPLANS Consortium, Ian N Bruce, Katherine Payne, Mark Lunt, Niels Peek, Nophar Geifman, Sean Gavan, Gillian Armitt, Patrick Doherty, Jennifer Prattley, Narges Azadbakht, Angela Papazian, Helen Le Sueur, Carmen Farrelly, Clare Richardson, Zunnaira Shabbir, Lauren Hewitt, Neil McHugh, Caroline Gordon, John Reynolds, Stephen Young, David Jayne, Vern Farewell, Li Su, Matthew Pickering, Elizabeth Lightstone, Alyssa Gilmore, Marina Botto, Timothy Vyse, David Lester Morris, D D’Cruz, Edward Vital, Miriam Wittmann, Paul Emery, Michael Beresford, Christian Hedrich, Angela Midgley, Jenna Gritzfeld, Michael Ehrenstein, David Isenberg, Mariea Parvaz, Jane Dunnage, Jane Batchelor, E Holland, Pauline Upsall

10.1136/lupus-2021-000584

May 31, 2022

Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus

Serena Fasano, Michele Iudici, Melania Alessia Coscia, Valentina Messiniti, Alessia Borgia, Rosella Tirri, Francesco Ciccia

10.1136/lupus-2022-000681

March 24, 2022

Inflammatory markers in saliva and urine reflect disease activity in patients with systemic lupus erythematosus

Guillermo Ruacho, Ronaldo Lira-Junior, Iva Gunnarsson, Elisabet Svenungsson, Elisabeth A Boström

10.1136/lupus-2021-000607

March 4, 2022

Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis

Melissa Northcott, Sarah Jones, Rachel Koelmeyer, Julie Bonin, Fabien Vincent, Rangi Kandane-Rathnayake, Alberta Hoi, Eric Morand

10.1136/lupus-2021-000625

February 23, 2022

ANA positivity and complement level in pleural fluid are potential diagnostic markers in discriminating lupus pleuritis from pleural effusion of other aetiologies

Der-Yuan Chen, Yen-Hsiang Huang, Yi-Ming Chen, Jeremy J W Chen, Tsung-Ying Yang, Gee-Chen Chang, Kuo-Tung Tang

10.1136/lupus-2021-000562

November 16, 2021

Microarray testing in patients with systemic lupus erythematosus identifies a high prevalence of CpG DNA-binding antibodies

Tammo Brunekreef, Maarten Limper, Rowena Melchers, Linda Mathsson-Alm, Jorge Dias, Imo Hoefer, Saskia Haitjema, Jacob M van Laar, Henny Otten

10.1136/lupus-2021-000531

November 1, 2021